EE200100666A - Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil - Google Patents

Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil

Info

Publication number: EE200100666A
Authority: EE; Estonia
Prior art keywords: protein aggregation; amyloid; inhibiting; isoindoline derivatives; imaging diagnostics
Prior art date: 1999-06-10

Application number

EEP200100666A

Other languages

English (en)

Inventor

Elizabeth Augelli-Szafran Corinne

Lai Yingjie

Theresa Sakkab Annette

Craswell Walker Lary

Original Assignee

Warner-Lambert Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-10

Filing date

2000-05-31

Publication date

2003-02-17

2000-05-31 Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company

2003-02-17 Publication of EE200100666A publication Critical patent/EE200100666A/et

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Optics & Photonics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Radiology & Medical Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EEP200100666A 1999-06-10 2000-05-31 Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil EE200100666A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13854399P	1999-06-10	1999-06-10
PCT/US2000/015073 WO2000076969A1 (en)	1999-06-10	2000-05-31	Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives

Publications (1)

Publication Number	Publication Date
EE200100666A true EE200100666A (et)	2003-02-17

Family

ID=22482508

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200100666A EE200100666A (et)	1999-06-10	2000-05-31	Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil

Country Status (38)

Country	Link
EP (1)	EP1192131B1 (et)
JP (1)	JP2003502313A (et)
KR (1)	KR20020012266A (et)
CN (1)	CN1156445C (et)
AP (1)	AP1398A (et)
AT (1)	ATE272623T1 (et)
AU (1)	AU777747B2 (et)
BG (1)	BG106291A (et)
BR (1)	BR0011446A (et)
CA (1)	CA2373394A1 (et)
CR (1)	CR6530A (et)
CZ (1)	CZ20014366A3 (et)
DE (1)	DE60012742T2 (et)
DK (1)	DK1192131T3 (et)
DZ (1)	DZ3262A1 (et)
EA (1)	EA004405B1 (et)
EE (1)	EE200100666A (et)
ES (1)	ES2223531T3 (et)
GE (1)	GEP20043407B (et)
HK (1)	HK1046283B (et)
HR (1)	HRP20020027A2 (et)
HU (1)	HUP0201586A2 (et)
IL (1)	IL146455A0 (et)
IS (1)	IS6162A (et)
MA (1)	MA26807A1 (et)
MX (1)	MXPA01011112A (et)
NO (1)	NO20015992L (et)
NZ (1)	NZ515619A (et)
OA (1)	OA11958A (et)
PL (1)	PL352294A1 (et)
PT (1)	PT1192131E (et)
SI (1)	SI1192131T1 (et)
SK (1)	SK17622001A3 (et)
TR (1)	TR200200257T2 (et)
UA (1)	UA64842C2 (et)
WO (1)	WO2000076969A1 (et)
YU (1)	YU86801A (et)
ZA (1)	ZA200109164B (et)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL352430A1 (en) *	1999-06-10	2003-08-25	Warner Lambert Co	Method of inhibiting agreggation of amyloid proteins and visualising amyloid deposits
US6972287B1 (en)	1999-06-10	2005-12-06	Pfizer Inc.	Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
PE20020394A1 (es)	2000-08-18	2002-06-21	Agouron Pharma	Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
CA2357450A1 (en) *	2000-09-29	2002-03-29	Warner-Lambert Company	Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis
GB0031302D0 (en) *	2000-12-21	2001-01-31	Glaxo Group Ltd	Napthalene derivatives
PE20040844A1 (es) *	2002-11-26	2004-12-30	Novartis Ag	Acidos fenilaceticos y derivados como inhibidores de la cox-2
GB2404855A (en) *	2003-07-07	2005-02-16	Pantherix Ltd	Arylcarboxylic acid derivatives and their therapeutic use
AR061623A1 (es)	2006-06-26	2008-09-10	Novartis Ag	Derivados de acido fenilacetico
CN102838532A (zh) *	2006-11-24	2012-12-26	Ac免疫有限公司	用于治疗与淀粉样物质或淀粉样蛋白有关的疾病的吡唑胺和噻唑胺衍生物
CA2676715A1 (en)	2007-02-12	2008-08-21	Merck & Co., Inc.	Piperazine derivatives for treatment of ad and related conditions
US20110293520A1 (en) *	2008-06-09	2011-12-01	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
WO2010089292A1 (en)	2009-02-06	2010-08-12	Ortho-Mcneil-Janssen Pharmaceuticals, Inc	Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh)	2009-02-19	2014-11-21	Janssen Pharmaceuticals Inc	作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
AU2010262036B2 (en)	2009-05-07	2014-10-30	Cellzome Limited	Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
JP2012532912A (ja)	2009-07-15	2012-12-20	ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド	ガンマセクレターゼモジュレーターとしての置換されたトリアゾールおよびイミダゾール誘導体
BR112012017310A2 (pt)	2010-01-15	2016-04-19	Janssen Pharmaceuticals Inc	derivados de triazol substituídos como moduladores de gama secretase
AU2012230348A1 (en)	2011-03-24	2013-08-29	Cellzome Limited	Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
KR101913135B1 (ko)	2011-07-15	2018-10-30	얀센 파마슈티칼즈, 인코포레이티드	감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체
US9181245B2 (en)	2012-05-16	2015-11-10	Janssen Pharmaceuticals, Inc.	Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease
CA2889249C (en)	2012-12-20	2021-02-16	Francois Paul Bischoff	Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators
CA2891755C (en)	2013-01-17	2021-10-26	Janssen Pharmaceutica Nv	Substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en)	2014-01-16	2020-02-18	Janssen Pharmaceutica Nv	Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
PT3133068T (pt) *	2014-04-14	2021-01-06	Shanghai hengrui pharmaceutical co ltd	Derivados de amida e sais farmacêuticos destes, método de preparação destes e aplicação medicinal destes
EP3186241B1 (en) *	2014-08-29	2020-10-07	CHDI Foundation, Inc.	Probes for imaging huntington protein
MA41051B1 (fr)	2014-10-06	2020-11-30	Vertex Pharma	Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
CA3019380A1 (en)	2016-03-31	2017-10-05	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CN109803962B (zh)	2016-09-30	2022-04-29	弗特克斯药品有限公司	囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物
MD3551622T2 (ro)	2016-12-09	2021-03-31	Vertex Pharma	Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
CN110225753B (zh) *	2017-01-28	2022-12-09	金凯(辽宁)生命科技股份有限公司	用于制备5-苯氧基-1(3h)异苯并呋喃酮的方法
US11253509B2 (en)	2017-06-08	2022-02-22	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
MA49631A (fr)	2017-07-17	2020-05-27	Vertex Pharma	Méthodes de traitement de la fibrose kystique
JP7121794B2 (ja)	2017-08-02	2022-08-18	バーテックスファーマシューティカルズインコーポレイテッド	ピロリジン化合物を調製するためのプロセス
CN109232533A (zh) *	2017-09-28	2019-01-18	北京越之康泰生物医药科技有限公司	氮杂环类衍生物、其制备方法及其医药用途
WO2019079760A1 (en)	2017-10-19	2019-04-25	Vertex Pharmaceuticals Incorporated	CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
EP3720849A2 (en)	2017-12-08	2020-10-14	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en)	2018-04-13	2021-02-17	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
KR20240035820A (ko)	2021-07-09	2024-03-18	플렉시움 인코포레이티드	Ikzf2를 조절하는 아릴 화합물 및 약학 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5552426A (en) *	1994-04-29	1996-09-03	Eli Lilly And Company	Methods for treating a physiological disorder associated with β-amyloid peptide

2000
- 2000-05-31 DE DE2000612742 patent/DE60012742T2/de not_active Expired - Fee Related
- 2000-05-31 YU YU86801A patent/YU86801A/sh unknown
- 2000-05-31 HU HU0201586A patent/HUP0201586A2/hu unknown
- 2000-05-31 UA UA2001117664A patent/UA64842C2/uk unknown
- 2000-05-31 MX MXPA01011112A patent/MXPA01011112A/es not_active Application Discontinuation
- 2000-05-31 EA EA200101133A patent/EA004405B1/ru not_active IP Right Cessation
- 2000-05-31 GE GE4625A patent/GEP20043407B/en unknown
- 2000-05-31 DZ DZ003262A patent/DZ3262A1/fr active
- 2000-05-31 DK DK00938023T patent/DK1192131T3/da active
- 2000-05-31 KR KR1020017015827A patent/KR20020012266A/ko not_active Withdrawn
- 2000-05-31 HK HK02107877.1A patent/HK1046283B/zh not_active IP Right Cessation
- 2000-05-31 IL IL14645500A patent/IL146455A0/xx unknown
- 2000-05-31 CZ CZ20014366A patent/CZ20014366A3/cs unknown
- 2000-05-31 SK SK1762-2001A patent/SK17622001A3/sk unknown
- 2000-05-31 OA OA1200100320A patent/OA11958A/en unknown
- 2000-05-31 AT AT00938023T patent/ATE272623T1/de not_active IP Right Cessation
- 2000-05-31 AU AU53120/00A patent/AU777747B2/en not_active Ceased
- 2000-05-31 HR HR20020027A patent/HRP20020027A2/hr not_active Application Discontinuation
- 2000-05-31 PL PL00352294A patent/PL352294A1/xx not_active Application Discontinuation
- 2000-05-31 CN CNB008087288A patent/CN1156445C/zh not_active Expired - Fee Related
- 2000-05-31 CA CA002373394A patent/CA2373394A1/en not_active Abandoned
- 2000-05-31 ES ES00938023T patent/ES2223531T3/es not_active Expired - Lifetime
- 2000-05-31 PT PT00938023T patent/PT1192131E/pt unknown
- 2000-05-31 TR TR2002/00257T patent/TR200200257T2/xx unknown
- 2000-05-31 NZ NZ515619A patent/NZ515619A/en unknown
- 2000-05-31 AP APAP/P/2002/002389A patent/AP1398A/en active
- 2000-05-31 EP EP00938023A patent/EP1192131B1/en not_active Expired - Lifetime
- 2000-05-31 EE EEP200100666A patent/EE200100666A/et unknown
- 2000-05-31 BR BR0011446-4A patent/BR0011446A/pt not_active IP Right Cessation
- 2000-05-31 WO PCT/US2000/015073 patent/WO2000076969A1/en not_active Ceased
- 2000-05-31 JP JP2001503829A patent/JP2003502313A/ja active Pending
- 2000-05-31 SI SI200030475T patent/SI1192131T1/xx unknown
2001
- 2001-11-06 ZA ZA200109164A patent/ZA200109164B/en unknown
- 2001-11-15 IS IS6162A patent/IS6162A/is unknown
- 2001-12-07 CR CR6530A patent/CR6530A/es not_active Application Discontinuation
- 2001-12-07 NO NO20015992A patent/NO20015992L/no not_active Application Discontinuation
2002
- 2002-01-03 MA MA26467A patent/MA26807A1/fr unknown
- 2002-01-09 BG BG106291A patent/BG106291A/bg unknown

Also Published As

Publication number	Publication date
HRP20020027A2 (en)	2005-02-28
OA11958A (en)	2006-04-13
AP1398A (en)	2005-04-21
PT1192131E (pt)	2004-11-30
CN1156445C (zh)	2004-07-07
EP1192131B1 (en)	2004-08-04
BG106291A (bg)	2002-05-31
NZ515619A (en)	2003-05-30
TR200200257T2 (tr)	2002-06-21
EA004405B1 (ru)	2004-04-29
CZ20014366A3 (cs)	2002-11-13
HUP0201586A2 (en)	2002-08-28
EP1192131A1 (en)	2002-04-03
CN1355790A (zh)	2002-06-26
HK1046283B (zh)	2005-01-07
NO20015992L (no)	2002-02-06
DE60012742T2 (de)	2005-01-13
WO2000076969A1 (en)	2000-12-21
IS6162A (is)	2001-11-15
ZA200109164B (en)	2003-02-06
BR0011446A (pt)	2002-03-19
ATE272623T1 (de)	2004-08-15
AP2002002389A0 (en)	2002-03-31
NO20015992D0 (no)	2001-12-07
MA26807A1 (fr)	2004-12-20
EA200101133A1 (ru)	2002-06-27
CA2373394A1 (en)	2000-12-21
SK17622001A3 (sk)	2003-06-03
CR6530A (es)	2004-03-24
JP2003502313A (ja)	2003-01-21
DZ3262A1 (fr)	2000-12-12
DK1192131T3 (da)	2004-12-13
IL146455A0 (en)	2002-07-25
SI1192131T1 (en)	2004-12-31
GEP20043407B (en)	2004-05-10
DE60012742D1 (de)	2004-09-09
YU86801A (sh)	2004-07-15
AU777747B2 (en)	2004-10-28
HK1046283A1 (en)	2003-01-03
PL352294A1 (en)	2003-08-11
KR20020012266A (ko)	2002-02-15
UA64842C2 (uk)	2004-03-15
MXPA01011112A (es)	2002-06-04
AU5312000A (en)	2001-01-02
ES2223531T3 (es)	2005-03-01

Publication	Publication Date	Title
EE200100666A (et)	2003-02-17	Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil
NO20003251D0 (no)	2000-06-22	Metode for magnetisk resonans avbildning
DE60217090D1 (de)	2007-02-08	Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
EP1171032A4 (en)	2008-10-29	PROCESS FOR IN VIVO IMAGING BY MAGNETIC RESONANCE
EE200100673A (et)	2003-02-17	Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks
EA200000274A3 (ru)	2003-02-27	Способы получения и промежуточные соединения для получения противораковых соединений
EE200200183A (et)	2003-06-16	Meetod polüisobuteenfenooli sisaldavate Mannichi aduktide saamiseks
NO20023333D0 (no)	2002-07-10	Fremgangsmåte for bildefokusering og apparat for avbildning av borehullsresistivitet
DE60030355D1 (de)	2006-10-12	Toner und Bildherstellungsverfahren
ATE275145T1 (de)	2004-09-15	Chinazolinderivate zur behandlung von tumoren
ATE293610T1 (de)	2005-05-15	2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
IT1302195B1 (it)	2000-07-31	Metodo e apparato per filtraggio di coerenza di immagini ultrasoniche.
DE60015555D1 (de)	2004-12-09	Abbildungsmethode mittels thermischem resonanz
NO20002517L (no)	2000-07-14	Magnetisk resonansavbildningsmidler for deteksjon av fysiologiske midler
EE200100383A (et)	2002-12-16	L-fenüülefriinvesinikkloriidi valmistamise meetod
NO990523D0 (no)	1999-02-04	FremgangsmÕte for fremstilling av kontrastmidler for magnetresonanstomografi
NO20004561D0 (no)	2000-09-13	Metode for magnetisk resonansavbildning
DE69933911D1 (de)	2006-12-21	Phasenempfindliches Inversions-Rückstellungsverfahren der Magnetresonanzbildgebung
NO20002115L (no)	2000-06-23	Magnetiske resonansavbildingsmidler for avlevering av terapeutiske midler
FI20021402L (fi)	2003-02-08	Menetelmä magneettiresonanssimittauksen kuvauksen homogenisoimiseksi
DE69710574D1 (de)	2002-03-28	Diclofenac/gamma-cyclodextrin klathrat komponente
TR200103562T2 (tr)	2002-04-22	Amiloid proteini toplanmasını önleme ve amiloid birikintilerini görüntüleme yönteminde kullanım için rodanin türevleri
FI982704A0 (fi)	1998-12-14	Digitaalinen kuvantamismenetelmä ja laitteita digitaalisessa kuvantamisessa
NO20022157D0 (no)	2002-05-06	Fremgangsmåte for behandling av medikamentavhengighet
SI1080076T1 (sl)	2004-04-30	Izboljšan postopek za pripravo farmacevtsko pomembnih norbenzomorfanskih derivatov